Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Johanne Seguin, Mostafa El Hajjam, Josette Legagneux, Sarah Diakhaby, Nathalie Mignet, et al.. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics, 2024, 16 (3), pp.315. ⟨10.3390/pharmaceutics16030315⟩. ⟨hal-04626840⟩
-
Julie Lecuelle, Caroline Truntzer, Debora Basile, Luigi Laghi, Luana Greco, et al.. Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts. EBioMedicine, 2024, 105, pp.105207. ⟨10.1016/j.ebiom.2024.105207⟩. ⟨hal-04626841⟩
Mots clés
HIV
ACTH
Polyomavirus
Survival
Gastric bypass
Lung adenocarcinoma
Prevention
BRAF
Invasive cutaneous squamous cell carcinoma
Cancer
Children
Staging
Cutaneous squamous cell carcinoma
Thrombosis
Cemiplimab
Surgical excision
Advanced
Chemotherapy
Mesenchymal stromal cells
Prognosis
Treatment
Colon cancer
ADN tumoral circulant
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Advanced melanoma
ALK rearrangement
Immunomodulation
Liver metastases
Biomarkers
BRAFV600E mutation
Colorectal carcinoma
Immunothérapie
TNM classification
Osimertinib
Radiotherapy
Safety
Wnt
Adverse events
Adjuvant FOLFOX
Adjuvant therapy
BRAF V600-mutation
Locally advanced
Non-small cell lung cancer
Plasma
Anti-Tumor pharmacology
Anti-CTLA-4
Melanoma
Antineoplastic agents
Antibody-drug conjugate
ADAMTS13
Resistance
Anti-PD1
Molecular targeted therapies
Immunotherapy
Abdominal pain
Toxicity
Crizotinib
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Langerhans cell histiocytosis
Diagnosis
Prognostic
2-chlorodeoxyadenosine
Dabrafenib
Anti-PD1 blockade
Chemoresistance
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Biomarker
Merkel cell carcinoma
Radiofrequency ablation
Sonic Hedgehog
Anti-PD-1 antibody
Cancer bronchique non à petites cellules
Targeted therapy
Nivolumab
Acute generalized exanthematous pustulosis
Trametinib
Metastatic cSCC
EGFR
Follow-up
Systemic therapy
Circulating cell-free DNA
Immune checkpoint inhibitor
ALK
Abscopal effect
Allelic imbalance
Circulating tumor DNA
Assisted reproductive techniques
Lung cancer
Colorectal cancer
Oncology
Adjuvant
BRAF V600E
Anti-PD-1
AML
AZD9291
Androgen insensitivity
Immunohistochemistry
Histiocytosis
Metastatic
COVID-19